FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4251434313> ?p ?o ?g. }

• W4251434313 abstract "Abstract Background The HER2 extracellular domain shed in blood (HER2 ECD ) is reported to rise and fall in parallel with HER2+ breast cancer behavior. In this study, we evaluated the clinical relevance of plasma HER2 ECD values in patients with metastatic breast cancer treated in the SAKK22/99 trial comparing trastuzumab monotherapy followed by trastuzumab-chemotherapy combination at progression versus upfront combination therapy. Methods Quantitative assessment of plasma HER2 ECD was performed in 133 patients at baseline; after 2-24 hours; at 3 weeks; at first response evaluation (8-9 weeks); and at tumor progression. Associations with tumor characteristics, disease course and trial treatment were evaluated. Results Baseline HER2 ECD levels were stable within 24 hours after the first trastuzumab injection. These plasma values correlated positively with the HER2 gene ratio (r s =0.39, P <0.001) and HER2 protein expression levels (r s =0.36, P <0.001) but not with ER/PR status of the primary tumor. HER2 ECD baseline levels were positively associated with the presence of visceral disease ( P =0.05) and poor patients’ outcome (Cox-regression: P =0.009). Patients with high baseline levels ( > 35ng/ml) had the worst overall survival ( P =0.03) if treated with upfront combination therapy. Conversely, patients with low HER2 ECD baseline values (<15ng/ml) had longer time to progression on combined trastuzumab-chemotherapy when first treated with trastuzumab monotherapy ( P =0.02). Monitoring HER2 ECD levels during the course of the trial revealed significant time ( P =0.001) and time-treatment arm interactions ( P =0.0007). Under upfront trastuzumab alone, the HER2 ECD levels remained stable until just before disease progression. In patients responding to combination treatment HER2 ECD levels decreased to > 20%. Conclusions Plasma HER2 ECD levels in patients with metastatic breast cancer reflect HER2 disease status. This robust biomarker might help identifying patients without visceral disease profiting from a sequential treatment’s modality. Monitoring HER2 ECD levels during trastuzumab monotherapy could help defining the optimal time to introduce chemotherapy." @default.
• W4251434313 created "2022-05-12" @default.
• W4251434313 creator A5006229315 @default.
• W4251434313 creator A5031581462 @default.
• W4251434313 creator A5031592069 @default.
• W4251434313 creator A5044589331 @default.
• W4251434313 creator A5061473697 @default.
• W4251434313 creator A5061698687 @default.
• W4251434313 creator A5065813790 @default.
• W4251434313 creator A5070351685 @default.
• W4251434313 date "2020-02-03" @default.
• W4251434313 modified "2023-10-16" @default.
• W4251434313 title "Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: Results of a randomized study - SAKK 22/99" @default.
• W4251434313 cites W1763604934 @default.
• W4251434313 cites W1971481885 @default.
• W4251434313 cites W1986291899 @default.
• W4251434313 cites W1987380783 @default.
• W4251434313 cites W1988610380 @default.
• W4251434313 cites W2024032315 @default.
• W4251434313 cites W2024896551 @default.
• W4251434313 cites W2075075174 @default.
• W4251434313 cites W2077778212 @default.
• W4251434313 cites W2087868278 @default.
• W4251434313 cites W2096205264 @default.
• W4251434313 cites W2097255042 @default.
• W4251434313 cites W2099117820 @default.
• W4251434313 cites W2128179232 @default.
• W4251434313 cites W2154655712 @default.
• W4251434313 cites W2163873687 @default.
• W4251434313 cites W2168953808 @default.
• W4251434313 cites W2567078974 @default.
• W4251434313 cites W2792392509 @default.
• W4251434313 cites W2889232066 @default.
• W4251434313 cites W2904225773 @default.
• W4251434313 doi "https://doi.org/10.21203/rs.2.11084/v5" @default.
• W4251434313 hasPublicationYear "2020" @default.
• W4251434313 type Work @default.
• W4251434313 citedByCount "0" @default.
• W4251434313 crossrefType "posted-content" @default.
• W4251434313 hasAuthorship W4251434313A5006229315 @default.
• W4251434313 hasAuthorship W4251434313A5031581462 @default.
• W4251434313 hasAuthorship W4251434313A5031592069 @default.
• W4251434313 hasAuthorship W4251434313A5044589331 @default.
• W4251434313 hasAuthorship W4251434313A5061473697 @default.
• W4251434313 hasAuthorship W4251434313A5061698687 @default.
• W4251434313 hasAuthorship W4251434313A5065813790 @default.
• W4251434313 hasAuthorship W4251434313A5070351685 @default.
• W4251434313 hasBestOaLocation W42514343131 @default.
• W4251434313 hasConcept C121608353 @default.
• W4251434313 hasConcept C126322002 @default.
• W4251434313 hasConcept C143998085 @default.
• W4251434313 hasConcept C2775930923 @default.
• W4251434313 hasConcept C2776694085 @default.
• W4251434313 hasConcept C2779786085 @default.
• W4251434313 hasConcept C50382708 @default.
• W4251434313 hasConcept C530470458 @default.
• W4251434313 hasConcept C71924100 @default.
• W4251434313 hasConceptScore W4251434313C121608353 @default.
• W4251434313 hasConceptScore W4251434313C126322002 @default.
• W4251434313 hasConceptScore W4251434313C143998085 @default.
• W4251434313 hasConceptScore W4251434313C2775930923 @default.
• W4251434313 hasConceptScore W4251434313C2776694085 @default.
• W4251434313 hasConceptScore W4251434313C2779786085 @default.
• W4251434313 hasConceptScore W4251434313C50382708 @default.
• W4251434313 hasConceptScore W4251434313C530470458 @default.
• W4251434313 hasConceptScore W4251434313C71924100 @default.
• W4251434313 hasLocation W42514343131 @default.
• W4251434313 hasLocation W42514343132 @default.
• W4251434313 hasLocation W42514343133 @default.
• W4251434313 hasOpenAccess W4251434313 @default.
• W4251434313 hasPrimaryLocation W42514343131 @default.
• W4251434313 hasRelatedWork W2023654245 @default.
• W4251434313 hasRelatedWork W2030434439 @default.
• W4251434313 hasRelatedWork W2050439103 @default.
• W4251434313 hasRelatedWork W2069175206 @default.
• W4251434313 hasRelatedWork W2092771806 @default.
• W4251434313 hasRelatedWork W2143625559 @default.
• W4251434313 hasRelatedWork W2218005127 @default.
• W4251434313 hasRelatedWork W2782589310 @default.
• W4251434313 hasRelatedWork W2937445726 @default.
• W4251434313 hasRelatedWork W2969515167 @default.
• W4251434313 isParatext "false" @default.
• W4251434313 isRetracted "false" @default.
• W4251434313 workType "article" @default.